Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049389 in Healthy Volunteers and Chronic Hepatitis B
NCT02952924Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of linvencorvir in Chronic Hepatitis B (CHB) (11 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events at 72 weeks, Time to Reach Maximum Concentration and 4 more. Started Dec 2016; status: completed.
02
Drugs
linvencorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02952924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952924.